Roku, Inc. (NASDAQ:ROKU)
Roku, Inc. is involved in creating streaming platform for delivering entertainment to the television. The Company’s products primarily includes Roku 4, Roku 3, Roku 2, Roku 1, Roku Streaming Stick and accessories such as cables, remote controls, power adapters and headphones. It operates primarily in the United States, Canada, the United Kingdom, the Republic of Ireland, Mexico and France. Roku, Inc. is based in SARATOGA, United States.
Roku, Inc. (NASDAQ:ROKU)’s Financial Overview
Roku, Inc. (NASDAQ) declined -1.47% yesterday to close its trading session at $39.57. The company has 1 year Price Target of $58.54. Roku, Inc. has 52-Week high of $77.57 and 52-Week Low of $26.3. The stock touched its 52-Week High on 77.57 and 52-Week Low on 26.30. The stock traded with the volume of 12.49 Million shares yesterday. The firm shows the market capitalization of $4.38 Billion.
Roku, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.09/share against the analyst consensus estimate of $-0.12/share. The difference between the actual and expected EPS is $0.03 a share with a surprise factor of 25%.
The firm is trading with SMA20 of 19.22 Percent, SMA50 of -1.73 Percent and SMA200 of -14.62 percent. Roku, Inc. has P/S value of 6.69 while its P/B value stands at 19.02. Similarly, the company has Return on Assets of -2.3 percent, Return on Equity of -4.5 percent and Return on Investment of -14.6 Percent. The company shows Gross Margin and Operating Margin of 44.8 percent and -1.8 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 13 analysts offering 12-month price forecasts for Roku Inc have a median target of 59.00, with a high estimate of 97.00 and a low estimate of 36.00. The median estimate represents a +49.10% increase from the last price of 39.57.
Roku, Inc. is estimated to report earnings on 02/20/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.01. The reported EPS for the same quarter last year was $0.06.
Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Gilead Sciences, Inc. (NASDAQ:GILD)’s Financial Outlook
The 23 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 86.00, with a high estimate of 106.00 and a low estimate of 71.00. The median estimate represents a +26.17% increase from the last price of 68.16.
Gilead Sciences, Inc. is expected* to report earnings on 02/04/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.63. The reported EPS for the same quarter last year was $1.6.
According to Zacks Investment Research, Gilead Sciences, Inc. has a Consensus Recommendation of 1.7. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 0.18% and closed its last trading session at $68.16. The company has the market capitalization of $88.02 Billion. The stock has 52-week high of $89.54 and 52-Week low of $60.32. The firm touched its 52-Week high on 89.54 and 52-Week low on 60.32. The company has volume of 5.67 Million shares. The company has a total of 1.29 Billion shares outstanding.
Gilead Sciences, Inc. (NASDAQ) in the last quarter reported its actual EPS of $1.84/share where the analyst estimated EPS was $1.63/share. The difference between the actual and Estimated EPS is $0.21. This shows a surprise factor of 12.9 percent.
The company has YTD performance of 8.97 percent. Beta for Gilead Sciences, Inc. stands at 1.2 while its ATR (average true range) is 2.19. The company has Weekly Volatility of 2.05%% and Monthly Volatility of 3.24%%.
Gilead Sciences, Inc. has distance from 20-day Simple Moving Average (SMA20) of 4.63%, Distance from 50-Day Simple Moving Average of 0.58 percent and Distance from 200-Day Simple Moving Average of -5.17%.
The Company currently has ROA (Return on Assets) of 2.4 percent, Return on Equity (ROE) of 7.4 Percent and Return on Investment (ROI) of 19.9% with Gross margin of 79.6 percent and Operating & Profit margin of 42% and 7.1% respectively.